RE: Moab! You asked "in breast cancer with metastasis, what is the average percentage recovery of CTCs20 Feb 2024 16:14
Moab. You posted:-
Carrot
2nd Nov 2022 7:00 am RNS Multiple downstream analysis techniques for CTCs.
Can I help you understand some of the longer words as well?
=========================================
Not only do you never seem to have anything good to say about Angle Plc, you are also routinely rude when you post your negative comments.
Part of the RNS:-
"The cytologic evaluation identified CTCs in 48.5% of all evaluable MBC patient samples independent of tumour subtype. CTCs were identified in 33.3% of newly diagnosed MBC patients, and in 56.8% of recurring or progressing MBC patients. Of the MBC patients' samples assessed by qRT-PCR, 52.7% were positive for at least one of the CTC-related genes and showed a general correlation with CTC count particularly at higher burden. There were 200 differentially expressed genes in the MBC patients, compared to healthy donors, as shown through RNA sequencing, with significant enrichment of cancer signalling pathway genes. HER2 amplification, detected via FISH analysis, was observed in a single patient sample with identifiable CTCs that also had HER2 positive tissue status."
========================================
What is your point? Cytologic evaluation is the analysis of cells from the body ***under a microscope*** which is different from a biopsy of a cct.!!!! In the presentation the breast cancer patients were 90% positive for cct's (see my previous post). It seems to me you are looking for problems that are not there? Mr Newland was "delighted" with this RNS. Even if the % of patients that cct to be found in their blood was lower it is better than zero. There is no other way remember!! LOL!!
The full RNS:-
https://www.lse.co.uk/rns/AGL/multiple-downstream-analysis-techniques-for-ctcs-hhkqa73ygzui4du.html
All IMHO.
Sign In
Follow the stocks
